SAE0217
Enhanced Microbial Transglutaminase
Glycosylation tolerant, for site-specific antibody bioconjugation
Synonym(e):
Protein-Glutamine-γ-Glutamyltransferase, Protein-glutamine:amine γ-glutamyltransferase, eMTG
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empfohlene Produkte
Rekombinant
expressed in E. coli
Qualitätsniveau
Spezifische Aktivität
≥30 units/mg protein
Versandbedingung
dry ice
Lagertemp.
-10 to -25°C
Allgemeine Beschreibung
eMTG (Enhanced Microbial Transglutaminase) is an enzyme that catalyzes the formation of new isopeptide bonds between the primary amine of a drug linker and glutamine residues at position Q295 of IgG-type antibodies to produce site-specifically conjugated antibody-drug conjugates (ADCs).
Anwendung
Site-specific conjugation is increasingly used in drug research, development, and manufacturing to produce ADCs and bioconjugates with defined drug-to-antibody ratios (DAR) since the resulting homogeneity improves safety and efficacy. Transglutaminase (TG)-mediated bioconjugation is a promising means of conjugating drug linkers specifically to the Q295 position of antibodies. However, its use traditionally requires antibody or glycan engineering since the adjacent glycosylation at N297 interferes with the TG reaction. If you’re interested in trying eMTG to make therapeutic ADCs but do not currently have the conjugation setup/expertise, please consider ADC Express™ Service for pre-clinical lead candidate selection.
Leistungsmerkmale und Vorteile
• Increased efficiency - with one-step bioconjugation for ADCs
• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product
• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates
• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.
• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product
• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates
• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.
Einheitendefinition
One unit will catalyze the formation of 1.0 micromole of hydroxamate per minute from N Z GLN-GLY and hydroxylamine at pH 6.0 at 37°C.
Signalwort
Danger
H-Sätze
P-Sätze
Gefahreneinstufungen
Resp. Sens. 1
Lagerklassenschlüssel
11 - Combustible Solids
WGK
WGK 1
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.